Thank you, morning, Chuck, and good everyone.
R&D that During and to patients. the I will our are ongoing we in our business, support policies affordable remarks, the access advancements advocate within progress for the work latest my making discuss pipeline, for
reshape before address including would to But our we regarding activities this these like I morning. company to topics, comments the I recent make a our few announced agreement
completed We very been have acquisition. recently busy. Therachon We the
soon. We close expect acquisition to Array the very
Mylan Upjohn just for consumer to We business the GSK our and create we business. with the agreement are announced our joint with venture proposed about for
to company a position long-term we be a innovative focus our dramatically actions smaller, singular able pipeline these move are a will pharma. all complete, the needle We more more focused, of in our in even be prospects. be terms science-based growth with will When believe where will on Pfizer
ways. growth improving In in our fact, we three profile see
otherwise given away. it growth more Lyrica We the higher we revenue go to the size, see sustainable. because five-year smaller We expect would CAGR growth And have starting our be be than will our the cliff will believe earlier been. LOE
still deliberate investors. the are invest returning breakthroughs we patients' company to continue make taking while are different fulfill our These is capital to a to We financial purpose; one flexibility have change steps our to in and better very even also will to that lives. that equipped growth Pfizer
solid. company-wide. Now, first let and performance I the about me talk revenues quarter the up In X% were operationally our been the quarter, pleased quarter. both half to the that the am second of has report year for
Our growth was driven again price by by offset volume increases, partially declines.
at on impact we quarter, pricing our in which our If the had this the of base increases quarter. the represented a an look volume decline growth revenue XX% even despite Group Biopharmaceuticals net bigger
biosimilars. shortages volume in and Lyrica the key continued saw a the XX% business. internationally, U.S. and growth supply the Overall, exclusivity and we markets and also brands in in U.S. loss growth operational in impact revenues of drivers emerging EU, offset the December These of were LOEs Enbrel partially in declines XXXX, several the by China, in in Viagra and product Upjohn's of decline in primarily hospital
the Group. the Biopharmaceuticals from with begin Let's results
grew its to business continue pleased performance be operationally quarter. this the in very We of line with which the top X%
and Inlyta, XX% strong, up was Oncology business operationally RETACRIT. by particularly driven Our Ibrance, Xtandi,
the billion. XX% to quarter Global Ibrance $X.X were operationally revenues in for up
is set to have of appears a the gained this quarter. ground which continues We the Ibrance during inhibitors small had international CDK believe them the news did to specific only growth accelerated or physicians the second most in is to additional markets, XX% for While to CDK of U.S. the result we target who rate had our growth not Overall, in been growth of patients. patients. prescribing from prescribed class good see effort U.S. come
grew For alliance leading branded is million. $XXX treat to novel the revenues for cancer. Xtandi U.S. XX% castrate-resistant operationally in prostate the Xtandi monotherapy to
for patients. Xtandi new We continue to increased see prescriptions
XX% FDA revenues included pembrolizumab XX% Inlyta of has increased This and the operationally Inlyta plus the $XXX cell in to for benefited from carcinoma. renal approvals growth of treatment U.S. Bavencio Inlyta million. Inlyta first-line in combination plus recent advanced
launch. Procrit, biosimilar Finally, $XX in RETACRIT, second a of our quarter revenues million the and start good to U.S. full for Epogen is with off following its in
arthritis product recent psoriatic Oncology, rheumatoid perform growth. continued operationally revenues up strong ulcerative growth We contributed also to And continued in arthritis were $XXX performances. volume had Beyond of Xeljanz XX% the launches we saw several well. to and to indication. other the Global million. colitis the
an believe option XXXX impact in the assessment, treatment update XXX,XXX level patients who appropriate to these and based in to arthritis, of in in benefit-risk information stage, initial business. expect colitis will on this debilitating U.S., and than Xeljanz rheumatoid strengths profile the than studied some we remain we patients At parts ulcerative impact the by in XX But has Xeljanz adult prescribing arthritis on commercial conditions. for the been the from trials we prescribed offset more of remains do prescribing. drug, confident more which to important that be enterprise our worldwide. clinical the an Regarding autoimmune are other suffering psoriatic
Eliquis revenues Global billion. in U.K. perform $X.X XX% to including number anticoagulant and the continues countries U.S. were to the well. now the is oral up XX operationally Eliquis one
been Tafamidis brand with the launch in recent with Our has name line expectations. our Vyndaqel of of
and unmet first the from for treatment As a previously patients suffering meets FDA-approved only ATTR-Cardiomyopathy, need. Vyndaqel
AI diagnosis are support use facilitate we of place by affordable early and solutions. and programs artificial in mean and through We to developing innovative I scintigraphy AI solutions. detection to the working access help for intelligence patients have
the ATTR-Cardiomyopathy approximately commercial significant U.S. trial in we have the approximately launch for drug In to increase rates compassionate since that in clinical have fact, patients already already added were on the and the XXX use seen patients XXX a and diagnosis
grow as numbers expect diagnosis increase. We rates these to and awareness
government revenues were some quarter first year. the by pediatric purchasing as quarter the Prevnar year-ago patterns in impacted negatively well this as during of XX
note important even for recent ACIP vaccine older. in to and However, in It it the recommendation the line. XX recommendation that year-to-date, a for its maintains adults is is with performing change
now decision it and be The patients. a also its to new vaccinate decision-making, called under with maintains individual status wherein their providers classification is at shared payers. between should clinical care the the made However, level health vaccine reimbursement
weekly believe but on XXXX not that parts feedback stage, level offset reduction will other some will At effective we the updated the of we this after the and impact is report, While strengths enterprise any until morbidity in impact posted. assess the mortality based the anticipate an customer the on recommendation language of business. is the we be in demand, publication by
continue constraints top our the In to sterile impact line injectables, U.S. manufacturing in supply
on to Once progress end steady back we the future. continue growth are to by business of in and we We solid expect remediation to toward contributor expect make improved a this to XXXX. significantly continue issues these be track, the to be
since March speak primarily in Now for driver the was X% Norvasc. included XXXX Revenues and were reforms Upjohn. driven about XXXX. a financial procurement our we implemented operational volume-based down business Upjohn China anticipated decline impact reforms operationally. XX% saw were Lipitor been in already has This by that was year let me unfavorably where guidance. The main our and beginning impacted of the These
win although growth remainder for where tender the for expected operational full in XX% Given the first Upjohn revenues operationally. in outlook year, by not of base. year to cities of the off to products mid-single for did growth XXXX we and expect our are digits volume grow lower second the quarter, half China the continued the a low In
addition, continue non-tender growth In products. see opportunities we to in
continued Viagra destocking for multi-source also and decline generic Lyrica We saw the as as industry-wide U.S. generic for competition in pricing in anticipation wholesaler X% primary competition drivers well a challenges. continued The were of
venture X% revenues operationally growth Healthcare, X% a Pfizer This partially the meaningful X% and and the created the the international our our occur our in X in we reflected to for to Healthcare U.S. August in Pfizer, customers For with operational We by anticipate joint our of Consumer shareholders. by quarter. value unlock Consumer expect offset GSK up markets, decline newly business formation were
to R&D. Turning
our progress or medicines indications. Since the last the making April of science. excited our XX, be We new with terms in continue our both with we of of on depth call and to for the earnings opportunities pipeline breadth approvals we have are seven received
carcinoma. in a for indication In with ulcerative the cancer. BAVENCIO biosimilar of the patients older, a moderately approved Vyndamax adult the combination U.S., now with for to Avastin first-line Inlyta, a and for treatment In which European patients new to of certain is approved of for renal has Rituxan, of patients metastatic and Inflectra, advanced patients Commission BRCA-mutated five active the has autoimmune for pediatric biosimilar non-small treatment of for and cell or Europe, for ALK-positive cardiomyopathy; colitis; TALZENNA FDA with lung ATTR age Ruxience, cancers approved and of severely years Vyndaqel and conditions; with cell breast for a treatment six advanced treatment the Lorviqua advanced cancer; locally cancer; biosimilar ZIRABEV the the different treatment types with inherited Remicade, for to of
ensure to as we working medicines soon have are as these We can. patients to access hard important
our the readout next-gen addition other months to vaccines, progress in infant In In pipeline. data we to with expect proof-of-concept we XX-valent pneumococcal X our coming vaccine continue study in Phase candidates approvals, from of the make a candidate. the
candidate conducted Our a potentially multivalent pregnant the vaccine Africa, being streptococcus B of one started highest region women, Phase of burdens in Group trials infection. this South study with devastating with in X a
on Phase to XXXX. decision selection half the that treat an a Phase planned for Xb currently Phase In study Dystrophy. initial the X basis are study providing clinical pivotal Duchenne Muscular our rare first could in data of the the therapy from Data presented dose begin disease, on investigational and we informed gene of Xb design potentially
hemophilia Alta With B TFPI updated subcutaneous gene therapy. Therapeutics, a criteria It is from A therapy for the to SB-XXX potential antibody pivotal A. pathway Study, designation medicine Phase evaluating X/XI The therapy results treatment this proof-of-concept. our severe investigational factor FDA partner regenerative the our advanced we granted for studies. monoclonal preset recently tissue for Sangamo weekly The advancing hemophilia of for inhibitor, and announced met
during cell. sickle readout for quarter We Rivipansel third in expect the pivotal
in with pivotal JAKX dermatitis. In patients Abrocitinib Inflammation set line Immunology, of a to study aged X and top our inhibitor atopic XX moderate severe we & older Phase results positive from
later another from program will in data study year. JADE be the Additional available this
initial based severe our the the we internal assessment X.X tanezumab tanezumab to milligram FDA, on data subcutaneous moderate osteoarthritis. of medicine, and discussion with for the In prioritize will
we We XXXX planned not are are continuing or by for late potential QX tanezumab. early but Japan. in maintain a dialogue U.S. future osteoarthritis an targeting lower with are and and X-milligram to regulatory assess submission the the or be EU open for submissions on will regulatory to time, followed back pathways At XXXX, regulatory in chronic this pain, dose for authorities
Oncology, pending next the existing stream the we decade. assets become into platform and Array's of the are the Array's as Pfizer's BioPharma. we we cancer Array key drivers Lastly, believe opportunity, acquisition of We solid our in about colorectal potential growth acquisition, expect fit business contributors research the move to the excited neatly royalty and three to into
expect We in near to the deal the term. close
As none patients sides improve Federal breakthroughs working the the Pfizer patients sense State of both to on and of affordability. at do we have aisle, to if said good them. on solutions in the any past, patients' common with both remains policymakers can't levels and committed will afford our
policy the on market biosimilars work Part capping before Finance laid February. Senate in in establishing the These a to include D, robust out-of-pocket continue in I value-based lower and costs arrangements to seniors' testimony solutions Committee out costs. We healthcare incentivizing
second solid and year. the of half quarter a delivered we summary, first In
Our producing medicines. pipeline is new
millions is business. commercial driving Our we the most gains, as of helping And volume us gains to to continue opposed see around world. strategy pricing reach important, patients our
the expect combination will respective colleagues to enhanced for and singular pending Mylan deliver shareholders. parts We focus this us patients, we a Upjohn have enable on of allow Upjohn and of both ahead, Looking business. and value to their believe Pfizer to the
named being CEO also to the combined Michael company. congratulate of I on want Goettler
the would lies personally know leave and him I sorry I from worked years help many that person having see the new with While company to leader tremendous for it getting Pfizer, opportunity that is seize be ahead. a to him the right closely strong
over to will provide for and on XXXX. of turn quarter our outlook I to remainder it the Frank Now, the details
